BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. trimmed its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 50.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,167 shares of the biotechnology company’s stock after selling 25,586 shares during the quarter. Envestnet Asset Management Inc.’s holdings in BioMarin Pharmaceutical were worth $1,363,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of BMRN. Quent Capital LLC purchased a new position in BioMarin Pharmaceutical during the 3rd quarter worth approximately $28,000. Hantz Financial Services Inc. increased its stake in shares of BioMarin Pharmaceutical by 480.2% in the second quarter. Hantz Financial Services Inc. now owns 1,056 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 874 shares during the period. Employees Retirement System of Texas purchased a new position in shares of BioMarin Pharmaceutical during the second quarter worth $58,000. Jones Financial Companies Lllp lifted its position in BioMarin Pharmaceutical by 88.1% during the third quarter. Jones Financial Companies Lllp now owns 1,401 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 656 shares during the period. Finally, True Wealth Design LLC boosted its holdings in BioMarin Pharmaceutical by 427.9% in the third quarter. True Wealth Design LLC now owns 1,985 shares of the biotechnology company’s stock valued at $108,000 after purchasing an additional 1,609 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Piper Sandler cut their price target on BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. Tudor Pickering set a $88.00 target price on BioMarin Pharmaceutical in a research note on Monday, November 3rd. Stifel Nicolaus set a $68.00 price target on BioMarin Pharmaceutical in a research report on Tuesday, February 24th. HC Wainwright lowered their price objective on BioMarin Pharmaceutical from $60.00 to $55.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Finally, Sanford C. Bernstein raised their price objective on shares of BioMarin Pharmaceutical from $90.00 to $94.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Fifteen investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.71.

BioMarin Pharmaceutical Stock Up 1.0%

Shares of NASDAQ BMRN opened at $61.73 on Monday. The firm has a market cap of $11.87 billion, a price-to-earnings ratio of 34.68, a price-to-earnings-growth ratio of 0.54 and a beta of 0.25. The company’s 50-day simple moving average is $58.91 and its 200-day simple moving average is $56.17. The company has a quick ratio of 3.50, a current ratio of 5.21 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical Inc. has a 52-week low of $50.76 and a 52-week high of $73.51.

Insider Transactions at BioMarin Pharmaceutical

In other news, EVP Gregory R. Friberg sold 6,326 shares of the company’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $60.38, for a total transaction of $381,963.88. Following the completion of the sale, the executive vice president owned 37,578 shares of the company’s stock, valued at $2,268,959.64. This represents a 14.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is currently owned by company insiders.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Sanford C. Bernstein published a bullish forecast calling for strong price appreciation for BMRN, which can lift investor expectations ahead of upcoming catalysts. Sanford C. Bernstein Forecast
• Positive Sentiment: Wells Fargo flagged BMRN as an attractive buy ahead of the Transcon‑CNP PDUFA decision, highlighting regulatory upside as a near‑term positive catalyst. Wells Fargo note
• Neutral Sentiment: Coverage pieces analyzing recent share rebound and DCF upside present valuation arguments but offer no clear catalyst; useful for investors modeling scenarios but not an immediate price driver. Valuation/DCF analysis
• Neutral Sentiment: Reported short‑interest data is effectively zero and contains apparent data errors (showing increases of “NaN”); this appears to be a reporting glitch and does not signal a meaningful short squeeze or surge in bearish positioning. (data entries dated Feb 26–27)
• Negative Sentiment: EVP Gregory Friberg sold 6,326 shares for roughly $382k at an average $60.38 on Feb. 26 — an insider sale that can weigh on sentiment, especially given the size relative to his remaining stake. Insider sale filing
• Negative Sentiment: HC Wainwright published a pessimistic forecast for BMRN, which could pressure sentiment among more risk‑sensitive investors. HC Wainwright note
• Negative Sentiment: Oppenheimer lowered its price target to $95, a cut that may temper upside expectations despite other bullish targets — contributes to mixed analyst messaging. Oppenheimer target cut

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.